Genovis AB (publ.), established in Lund, Sweden, in 1999, specializes in the creation and provision of advanced reagents essential for drug discovery and development. The company serves a diverse client base within the pharmaceutical and medical device sectors. Its core offerings predominantly feature a range of enzymes designed for precise modification and analysis of immunoglobulins (IgG).